Sujal M.  Patel net worth and biography

Sujal Patel Biography and Net Worth

Sujal Patel is the co-founder of Nautilus Biotechnology, a company at the intersection of innovation.  Nautilus is building a high-throughput, low-cost platform for analyzing and quantifying the human proteome.  Prior to Nautilus, Patel founded Isilon Systems in 2001, a storage company that built for the future of unstructured, file-based data which required a new storage paradigm.  In 2006, Isilon completed one of the most successful initial public offerings of the year.  From 2007 to 2010, Patel, as CEO, led Isilon during a period of profound growth, improving operating margins from -37.5% to +20%.

Isilon was acquired by EMC in December, 2010 for $2.5 Billion. Patel served as the President of EMC’s Isilon Storage Division from the acquisition until November, 2012, driving significant revenue growth, market expansion and organizational scale.

Prior to EMC and Isilon, Patel served in various engineering roles at RealNetworks, Inc., in part as chief architect behind the company’s second-generation core media delivery system.

Patel holds nineteen patents in the areas of storage, networking, and media delivery, is a well-known speaker on entrepreneurship, and has received a variety of industry awards.  Currently Patel serves on the board of directors at Qumulo and Rainier Scholars.

He graduated from the University of Maryland College Park in 1996 with a degree in Computer Science.

What is Sujal M. Patel's net worth?

The estimated net worth of Sujal M. Patel is at least $23.35 million as of March 11th, 2024. Mr. Patel owns 10,064,488 shares of Nautilus Biotechnology stock worth more than $23,349,612 as of November 21st. This net worth approximation does not reflect any other assets that Mr. Patel may own. Additionally, Mr. Patel receives an annual salary of $827,240.00 as CEO at Nautilus Biotechnology. Learn More about Sujal M. Patel's net worth.

How old is Sujal M. Patel?

Mr. Patel is currently 49 years old. There are 7 older executives and no younger executives at Nautilus Biotechnology. Learn More on Sujal M. Patel's age.

What is Sujal M. Patel's salary?

As the CEO of Nautilus Biotechnology, Inc., Mr. Patel earns $827,240.00 per year. Learn More on Sujal M. Patel's salary.

How do I contact Sujal M. Patel?

The corporate mailing address for Mr. Patel and other Nautilus Biotechnology executives is 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003. Nautilus Biotechnology can also be reached via phone at 206-333-2001 and via email at [email protected]. Learn More on Sujal M. Patel's contact information.

Has Sujal M. Patel been buying or selling shares of Nautilus Biotechnology?

Sujal M. Patel has not been actively trading shares of Nautilus Biotechnology during the last quarter. Most recently, on Monday, March 11th, Sujal M. Patel bought 12,044 shares of Nautilus Biotechnology stock. The stock was acquired at an average cost of $2.84 per share, with a total value of $34,204.96. Following the completion of the transaction, the chief executive officer now directly owns 10,064,488 shares of the company's stock, valued at $28,583,145.92. Learn More on Sujal M. Patel's trading history.

Who are Nautilus Biotechnology's active insiders?

Nautilus Biotechnology's insider roster includes Matthew Mcilwain (Director), Anna Mowry (CFO), Matthew Murphy (General Counsel), Sujal Patel (CEO), and Matthew Posard (Director). Learn More on Nautilus Biotechnology's active insiders.

Are insiders buying or selling shares of Nautilus Biotechnology?

In the last year, Nautilus Biotechnology insiders bought shares 3 times. They purchased a total of 38,303 shares worth more than $108,316.27. In the last year, insiders at the sold shares 2 times. They sold a total of 82,031 shares worth more than $234,728.97. The most recent insider tranaction occured on September, 23rd when VP Mary E. Godwin sold 47,031 shares worth more than $134,978.97. Insiders at Nautilus Biotechnology own 40.5% of the company. Learn More about insider trades at Nautilus Biotechnology.

Information on this page was last updated on 9/23/2024.

Sujal M. Patel Insider Trading History at Nautilus Biotechnology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/11/2024Buy12,044$2.84$34,204.9610,064,488View SEC Filing Icon  
3/7/2024Buy18,854$2.89$54,488.0610,050,014View SEC Filing Icon  
3/5/2024Buy7,405$2.65$19,623.2510,021,893View SEC Filing Icon  
8/8/2022Buy8,346$2.93$24,453.7810,014,488View SEC Filing Icon  
8/5/2022Buy41,654$2.92$121,629.6810,006,142View SEC Filing Icon  
5/9/2022Buy50,000$3.96$198,000.009,964,488View SEC Filing Icon  
3/3/2022Buy50,000$3.60$180,000.00View SEC Filing Icon  
11/30/2021Buy161,978$4.72$764,536.16View SEC Filing Icon  
See Full Table

Sujal M. Patel Buying and Selling Activity at Nautilus Biotechnology

This chart shows Sujal M Patel's buying and selling at Nautilus Biotechnology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Nautilus Biotechnology Company Overview

Nautilus Biotechnology logo
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $2.41
Low: $2.28
High: $2.42

50 Day Range

MA: $2.72
Low: $2.24
High: $3.08

2 Week Range

Now: $2.41
Low: $2.19
High: $3.45

Volume

63,546 shs

Average Volume

78,722 shs

Market Capitalization

$302.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23